Influenza and leptospirosis claim nearly 300 lives in Kerala this season

By mid-September, Kerala was in the grip of two diseases that had together claimed nearly 300 lives. Influenza and leptospirosis, once managed as seasonal nuisances, had become major killers across the state, forcing doctors and health officials to confront patterns they had not seen in previous years.

The numbers told the story. As of September 15, Kerala had recorded 10,244 cases of influenza—primarily the H1N1 strain, along with H2N3 and Influenza B—resulting in 109 confirmed deaths. Leptospirosis had claimed 100 confirmed lives, with another 78 deaths still classified as probable. The influenza toll alone represented a sharp climb from what the state had experienced before. Across India, the picture was similar: almost every state was reporting a surge in H1N1 cases. Health officials pointed to a combination of factors—erratic weather patterns, sustained heat and humidity, and possible mutations in the seasonal flu virus itself—as likely drivers of the spike.

The elderly were dying at a rate that alarmed public health experts. H1N1 was claiming a disproportionately high number of senior citizens, prompting calls for the government to prioritize flu vaccination programs for older populations. Yet the official case count almost certainly understated the true burden. The Health Department's guidelines for H1N1 did not recommend routine testing for mild cases; only patients arriving at hospital outpatient departments with serious symptoms were being tested. This meant the figures reported through the Integrated Disease Surveillance Programme captured only the sickest—not the actual number of people infected in the community.

Influenza presents like a common cold: fever, chills, sore throat, cough, body ache. But in vulnerable populations—the elderly, the pregnant, those with underlying conditions—it could turn severe. A health official explained the transmission risk plainly: the virus spreads through respiratory droplets and contaminated surfaces. Hospitals themselves could become transmission points if visitors and patients did not wear masks and practice respiratory hygiene. For people with mild symptoms, home isolation and supportive care were sufficient; they did not need testing or the antiviral drug Oseltamivir. But those with high fever, persistent symptoms, or other illnesses needed to see a doctor and start Oseltamivir early. The warning signs that demanded hospitalization and intensive care were breathlessness, chest pain, and low oxygen saturation.

Leptospirosis presented a different challenge. The disease's early symptoms overlapped with any viral fever, making diagnosis difficult. By the time it was identified, the infection had often progressed too far. In response, doctors in peripheral clinics were now being instructed to start doxycycline in all fever cases without respiratory symptoms, since the antibiotic had proven effective at any stage of the illness. Yet those at highest occupational risk—farmers, manual sanitation workers, gardeners, dairy farmers—were not taking prophylactic doxycycline as directed. Health officials pointed out that local self-governing bodies should be providing protective gear to these workers, a step that had not been consistently implemented.

Doctors were urging people not to self-treat and to stay home if symptoms worsened or did not improve. Early use of Oseltamivir could make a decisive difference. In the private sector, physicians were recommending the annual flu vaccine to elderly patients and those with chronic conditions who could afford it, since vaccination reduced infection risk and, even when breakthrough infections occurred, prevented serious disease, hospitalization, and death. The state was learning, in real time, that a disease that felt like a cold could kill, and that prevention and early treatment were not luxuries but necessities.